COVID19-HCQ

Hydroxychloroquine (HCQ)

Population PBPK/PD

Hydroxychloroquine has been shown to inhibit SARS-CoV, MERS-Cov, and SARS-CoV-2 (the pathogen responsible for COVID-19) growth in vitro.

The simulations are presented to inform researchers and provide a tool for discussing target concentrations in the relevant tissue (lung) over time. Not presented is the variability of target concentration, but between-subject variability was simulated.

The simulations have not accounted for differences in protein binding between the in vitro cell culture systems and protein binding in either plasma or lung. Indeed in lung it is possible that, due to its dibasic nature, HCQ could accumulate in the acidic lysosomes of alveolar macrophages secondary to ionic trapping. The current simulations are for lung tissue. The Simcyp® Simulator has the potential capability of exploring concentrations in lung substructures (ie lung model), but that model was not incorporated in the current simulations.

The in silico workbench is intended for use by researchers to assist with clinical trial design and for exploratory and educational purposes. It is NOT intended for use in the diagnosis, cure, mitigation or treatment of any disease. Data provided are not intended to suggest that any product and/or dosing regimen are safe and effective for any use and are for informational purposes only. Please see Terms and Conditions for additional information.